Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome
NCT: NCT06050265 · ACTIVE_NOT_RECRUITING
Brief Summary
PCOS is the most common endocrine disorder of reproductive aged women. In addition to menstrual and endocrine abnormalities, PCOS is characterized by insulin resistance and glycemic dysregulation. The pattern of glycemic abnormalities among patients with PCOS may be different than the general population, as evidenced by invasive, time consuming, and costly procedures such as the euglycemic clamp or oral glucose tolerance test. Continuous glucose monitoring (CGM) offers an opportunity to evaluate glycemic status in real world conditions. Furthermore, use of a CGM has been found to improve glycemic status among those with prediabetes and diabetes, but little is known about utility among patients with PCOS. The investigators thus seek to 1) characterize glycemic status using CGM among patients with PCOS and 2) assess the impact of CGM use on metabolic and reproductive health in patients with PCOS.
Frequently Asked Questions
What is Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome?
Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome is a clinical trial registered under NCT06050265. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT06050265?
The current status of NCT06050265 (Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome) is: ACTIVE_NOT_RECRUITING.
When did Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome start?
Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome started on 2023-11-29.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.